

INDEX

CONTENTS	Page No.
List of Abbreviations	i-ii
List of Figures	iii-iv
List of Tables	v
Preface	vi-vii
CHAPTER-1 INTRODUCTION	1-13
1.1. Drug Design, Discovery and Development	1
1.2. Epilepsy: An Overview	3
1.3. GABA Hypothesis & Epilepsy	8
1.3.1. GABA Synthesis and Metabolism	9
1.3.2. GABA Receptors	9
1.3.3. GABA Transporters	10
1.4. Piperidine 3-Carboxylic Acid (Nipecotic Acid)	11
CHAPTER-2 REVIEW OF LITERATURE	14-26
2.1. Nipecotic Acid: An <i>In Vitro</i> GABA Reuptake Inhibitor	14
2.2. Piperidine-3-Carboxylic Acid Derivatives as Anticonvulsants	15
2.3. Naphthalene Derivatives as Anticonvulsants	23
CHAPTER-3 RATIONALE, OBJECTIVE AND PLAN OF WORK	27-29
3.1. Rationale and Objective	27
3.2. Plan of Work	28
CHAPTER-4 EXPERIMENTAL	30-43
4.1. Chemistry	30
4.1.1. Chemicals and Reagents	30
4.1.2. Series 1	30
4.1.2.1. Method of Preparation	30
4.1.2.2. Reaction Mechanism for Series 1	31
4.1.3. Series 2	32
4.1.3.1. Method of Preparation	32
4.1.3.2. Reaction Mechanism for Series 2	34
4.1.4. Characterisation of Synthesised Compounds	34
4.1.4.1. Physicochemical Characterisation	35
4.1.4.2. Spectral Characterisation and Elemental Analysis	36
4.2. Biological Activity of Series 1	37
4.2.1. Animals	37
4.2.2. Drug Administration	37
4.2.3. Evaluation of <i>In Vivo</i> Anti-Convulsant Activity	37

CONTENTS	Page No.
4.2.3.1. sc-PTZ Induced Seizures in Mice	37
4.2.3.2. Pilocarpine Induced Seizures in Mice	38
4.2.3.3. DMCM Induced Seizures in Mice	38
4.2.4. Rota-rod Performance Test in Mice	38
4.2.5. MTT Assay on Neuroblastoma Cell Line (SH-SY5Y)	39
4.2.6. In Vitro Parallel Artificial Membrane BBB Permeability Assay (PAMPA)	39
4.3. Biological Activity of Series 2	40
4.4. Statistical analysis	40
4.5. Computational Studies	40
4.5.1. Homology Modelling of GAT-1	40
4.5.2. <i>In Silico</i> Docking	41
4.5.3. Molecular Dynamics (MD)	42
4.4.2.1. MD Simulation Protocol for Compound 4i	42
4.4.2.1. MD Simulation Protocol for Compound 5w	42
4.5.4. Prediction of drug likeliness and <i>in silico</i> ADME	43
CHAPTER-5 RESULTS AND DISCUSSION	44-92
5.A. Synthesis of Acetonaphthones Tethered Piperidine-3-Carboxylic Acid Derivatives. [series 1]	44-67
5.A.1. Chemistry	44
5.A.1.1. Physicochemical Characterisation	44
5.A.1.2. Spectral Characterisation and Elemental Analysis	45
5.A.2. Biological Activity	51
5.A.2.1. Evaluation of Anticonvulsant Activity	51
5.A.2.2. Rota-rod Performance Test in Mice	54
5.A.2.3. Cell viability and neurotoxicity (MTT Assay)	55
5.A.2.4. <i>In Vitro</i> PAMPA-BBB Assay	56
5.A.3. Computational Studies	80
5.A.3.1. Homology modeling of GAT-1	58
5.A.3.2. <i>In Silico</i> Docking	60
5.A.3.3. <i>In Silico</i> Molecular Dynamics	63
5.A.3.4. Estimation of "Drug-Like" Properties	66
5.B. 5,6-diphenyl-1,2,4-triazine-3(2 <i>H</i>)-ones bearing five-member (1,3,4 oxadiazole/thiadiazole, 1,2,4-triazole) heterocyclic moieties [Series 2]	68-92
5.B.1. Chemistry	68
5.B.1.1. Physicochemical Characterisation	68

CONTENTS	Page No.
5.B.1.2. Spectral Characterisation and Elemental Analysis	70
5.B.2. Biological Activity	79
5.B.2.1. <i>In Vitro</i> PAMPA-BBB Assay	79
5.B.2.2. Evaluation of Anticonvulsant Activity	81
5.B.2.3. Rota-rod Performance Test in Mice	84
5.B.2.4. . Cell viability and neurotoxicity (MTT Assay)	85
5.B.3. Computational Studies	85
5.B.3.1. Homology modeling of GAT-1	85
5.B.3.2. <i>In Silico</i> Docking	86
5.B.3.3. <i>In Silico</i> Molecular Dynamics	89
5.B.3.4. Estimation of “Drug-Like” Properties	91
CHAPTER-6 SUMMARY AND CONCLUSION	93-96
CHAPTER-7 REFERENCES	97-113
CHAPTER-8 APPENDIX	114-125
8.1. ¹ H and ¹³ C Spectra of Representative Compounds from Series 1	114
8.2. ¹ H and ¹³ C Spectra of Representative Compounds from Series 2	120
LIST OF RESEARCH PAPERS AND PRESENTATIONS	
REPRINTS OF PUBLISHED RESEARCH PAPERS	
